Last $2.14 USD
Change Today -0.06 / -2.73%
Volume 98.5K
GNVC On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

genvec inc (GNVC) Snapshot

Open
$2.21
Previous Close
$2.20
Day High
$2.23
Day Low
$2.11
52 Week High
01/23/14 - $4.25
52 Week Low
10/15/14 - $1.61
Market Cap
37.0M
Average Volume 10 Days
65.1K
EPS TTM
$-0.34
Shares Outstanding
17.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENVEC INC (GNVC)

Related News

No related news articles were found.

genvec inc (GNVC) Related Businessweek News

No Related Businessweek News Found

genvec inc (GNVC) Details

GenVec, Inc. operates as a biopharmaceutical company that uses differentiated and proprietary technologies to create therapeutics and vaccines. The company develops its product candidates through collaborations with various companies and organizations, including Novartis AG, Merial Limited, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of various human and animal health concerns. Its development programs address various therapeutic areas, such as hearing loss and balance disorders; and vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, dengue fever, and malaria. The company is also involved in developing vaccines against foot-and-mouth disease in the area of animal health. GenVec, Inc. was founded in 1992 and is based in Gaithersburg, Maryland.

11 Employees
Last Reported Date: 03/28/14
Founded in 1992

genvec inc (GNVC) Top Compensated Officers

Chief Executive Officer, President, Corporate...
Total Annual Compensation: $316.3K
Senior Vice President of Development
Total Annual Compensation: $278.1K
Chief Scientific Officer
Total Annual Compensation: $310.7K
Compensation as of Fiscal Year 2013.

genvec inc (GNVC) Key Developments

GenVec, Inc. Announces Executive Changes

On December 5, 2014, the board of directors of GenVec, Inc. designated James V. Lambert, to serve as the company's principal financial officer and principal accounting officer, effective immediately. Mr. Lambert will continue in his role as senior director, accounting and finance, a position he has held since 2010, prior to which he served in a variety of positions at the company since October 2006, including Senior Controller. He will also now serve as corporate controller and treasurer. Douglas J. Swirsky, who previously also served as the company's chief financial officer, principal financial officer and principal accounting officer, will no longer serve in those capacities. Mr. Swirsky will continue in his role as the company's president and chief executive officer and corporate secretary.

GenVec, Inc. Appoints Stegman & Company as Auditor

GenVec, Inc. at its AGM held on December 5, 2014, the shareholders approved the appointment of Stegman & Company as the independent registered public accounting firm for the year ending December 31, 2014.

GenVec, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Expects Cash Burn for 2014

GenVec, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the three-month period ended September 30, 2014, the company reported a net loss of $1.6 million or $0.10 per basic and diluted share on revenues of $0.3 million as compared to a net loss of $3.0 million or $0.23 per basic and diluted share on revenues of $1.6 million in the same period in the prior year. The decrease in revenue for the three-month period ended September 30, 2014 was primarily due to a decrease in revenue of $1.4 million associated with the malaria vaccine development efforts at the U.S. Naval Medical Research Center which was terminated in July 2013. This decrease was partially offset by an increase in revenue of $0.1 million associated with the animal health program which resulted from increased work scope. Loss from operations was $1.605 million against $2.963 million a year ago. For the nine-month period ended September 30, 2014, the company reported a net loss of $4.2 million or $0.27 per basic and diluted share on revenues of $2.5 million as compared to a net loss of $9.1 million or $0.71 per basic and diluted share on revenues of $3.5 million in the same period in the prior year. The decrease in revenue for the nine-month period ended September 30, 2014 primarily resulted from a decrease of $1.5 million associated with its malaria program. Additionally, there were reductions in revenue of $0.5 million with respect to its FMD program and $0.6 million because of reduced work scope and grant work performed for NIH programs and malaria programs. Loss from operations was $4.245 million against $9.148 million a year ago. For 2014, the company expects cash burn between $6 million and $7 million not including milestones from the Novartis collaboration. The company believes that existing resources, combined with anticipated near-term milestones, are sufficient to fund the company's operations into the foreseeable future.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNVC:US $2.14 USD -0.06

GNVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $7.31 USD +1.70
Eurocine Vaccines AB kr13.00 SEK -0.35
Genocea Biosciences Inc $7.54 USD +0.01
Vical Inc $1.04 USD -0.03
ZIOPHARM Oncology Inc $4.93 USD +0.13
View Industry Companies
 

Industry Analysis

GNVC

Industry Average

Valuation GNVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.7x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENVEC INC, please visit www.genvec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.